The development of novel biomarkers (including inflammatory biomarkers, such as CCL20) and the use of artificial intelligence tools have been suggested for earlier detection of CKD, and redefinition of risk based on age-adapted eGFR values has been suggested to aid in this purpose [39,40,41,42]. The gene discussed is CCL20; the disease is chronic kidney disease.